^
Association details:
| Biomarker: | IL32 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IL-32? potentiates tumor immunity in melanoma
Excerpt:
...increased baseline IL-32 gene expression was associated with response to nivolumab and pembrolizumab in two independent human melanoma patient cohorts, implying IL-32 as a predictive biomarker for anti-PD-1 therapy.
DOI:
10.1172/jci.insight.138772
